AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

MLL gene rearrangement not pathogenic mechanism in de novo MDS.

Vaccine Weekly

| May 05, 2004 | COPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2004 MAY 5 - (NewsRx.com & NewsRx.net) -- Mixed lineage leukemia gene rearrangement is not a pathogenic mechanism in de novo myelodysplastic syndromes.

"The mixed lineage leukemia (MLL) gene has been identified in 11q23 translocations. The aim of the present study is the investigation of the frequency of MLL gene rearrangements in cases of de novo myelodysplastic syndromes (MDS). Sixty-two patients with de novo MDS were included in the analysis," scientists in Greece report.

"The detection of MLL gene rearrangements was performed by Southern blot. Clonal karyotypic abnormalities were found in 15/50 (30%) cases. 11q23 abnormalities were not detected. One case with RAEB and a complex karyotype presented a del (11)(q13); further analysis by FISH revealed loss of one copy of MLL gene in all metaphases. Southern blot revealed germline bands in all cases using Eco RI and in 61/62 cases with Bam HI. The case with RAEB and a del (11)(q13) revealed a rearranged band following only BamHI digestion, but not Eco RI," reported V. Pappa and ...

Related articles from newspapers, magazines, journals, and more
MLL gene rearrangement not pathogenic mechanism in de novo MDS.
Newspaper article from: Drug Week May 7, 2004 700+ words
...pathogenic mechanism in de novo myelodysplastic...lineage leukemia (MLL) gene has been identified...the frequency of MLL gene rearrangements in cases of de novo myelodysplastic...Hematology (Absence of MLL gene rearrangement in de novo ...
Segmental Tandem Triplication of the MLL Gene in an Intravascular Large B-Cell...
Magazine article from: Archives of Pathology & Laboratory Medicine Deisch, Jeremy; Fuda, Franklin "Buddy"; Chen, Weina; Karandikar, Nitin; Arbini, Arnaldo A; Zhou, Xin J; Wang, Huan-You September 1, 2009 700+ words
...IVLBCL) and the mixed lineage leukemia (MLL) gene has never been demonstrated. Here, we...confirmed the presence of 3 copies of the MLL gene on the derivative chromosome 11. From...relationship between the mixed lineage leukemia (MLL) gene and IVLBCL has not yet been established...
Etoposide treatment triggers chimeric Mll gene fusions in vitro.
Newspaper article from: Genomics & Genetics Weekly January 16, 2004 700+ words
...Etoposide treatment triggers chimeric Mll gene fusions in vitro. According to recent research from Tennessee, "MLL gene fusions are the hallmark of more than...etoposide triggers the formation of Mll gene fusions, a critical step for the development...
Is topoisomerase II implicated in translocations involving the MLL...
Magazine article from: Proceedings of the North Dakota Academy of Science Reinholdt, Michelle L. Townsend, Jessica A. Super, Heidi J. April 1, 2005 700+ words
The Myeloid Lymphoid Leukemia (MLL) breakpoint cluster region is located on the long arm of chromosome 11. In this 8.3 kilobase (kb) section, specific, reciprocal translocations are common. A translocation occurs when two non-homologous chromosomes exchange DNA with one another. MLL translocations
De Novo Pharmaceuticals Ltd Announces a Major Initiative to Develop a...
Press release article from: PR Newswire February 4, 2002 700+ words
CAMBRIDGE, UK and LONDON -- De Novo Pharmaceuticals (De Novo) and Sun Microsystems (TM) have today announced a joint...develop a comprehensive chemoinformatics platform. De Novo and SUN will pool their resources to co-develop a comprehensive...
De Novo Pharmaceuticals Ltd Announces a Major Initiative to Develop a...
Press release article from: PR Newswire October 16, 2001 700+ words
...United Kingdom, Oct. 16 /PRNewswire/ -- De Novo Pharmaceuticals Ltd, Cambridge, UK, ("De Novo") announced today that they have entered...development collaboration with Roche in the area of de novo drug design. Under the terms of the agreement...
De novo bank exit.
Magazine article from: Journal of Money, Credit & Banking DeYoung, Robert October 1, 2003 700+ words
...recent research indicates that these "de novo" banks tend to locate in post-merger...1990s. The long-run probability of de novo bank exit (by failure, acquisition...used to construct hazard functions for de novo failure, acquisition, and conversion...
De Novo Pharmaceuticals and Peakdale Molecular Announce Strategic Alliance.
Press release article from: PR Newswire April 1, 2003 700+ words
...CAMBRIDGE, UK, April 1 /PRNewswire/ -- De Novo Pharmaceuticals (De Novo) and Peakdale Molecular (Peakdale) announced...skills in molecular design and chemistry synthesis. De Novo has world-leading proprietary expertise for the...
For more facts and information, see all results
©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA